Navigation Links
Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Date:2/17/2011

TARRYTOWN, N.Y., Feb. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the full year and fourth quarter of 2010 and provided an update on development programs and upcoming milestones.  

"2010 was a very productive year for Regeneron as we reported positive Phase 3 results in four clinical trials: two with VEGF Trap-Eye in wet age-related macular degeneration, called wet AMD, one with VEGF Trap-Eye in central retinal vein occlusion, and one with ARCALYST® for the prevention of gout flares in patients initiating uric-acid lowering therapy," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "We expect regulatory applications to be filed in the first half of 2011 for marketing approval in the U.S. and Europe for VEGF Trap-Eye in wet AMD.  We also look forward to reporting results from additional Phase 3 trials in central retinal vein occlusion and gout and from two Phase 3 trials with aflibercept in cancer."

"In anticipation of potential product approvals," Dr. Schleifer added, "we are continuing to build our commercialization capabilities.  We are also advancing our earlier-stage pipeline which currently includes eight fully-human monoclonal antibodies in clinical development for the treatment of various diseases and conditions including elevated LDL cholesterol, rheumatoid arthritis, atopic dermatitis, and cancer.  We anticipate Phase 2 data from some of these programs in 2011."

"We entered 2011 in a strong financial position to support our development and commercialization activities," commented Murray A. Goldberg, Chief Financial Officer, "with approximately $627 million in cash and securities, following a successful public offering of Common Stock in October 2010."

Clinical Programs UpdateVEGF Trap-Eye (aflibercept opht
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets ... Chinese Medical X-ray Film Industry Report 2014" report ... Global And Chinese Medical X-Ray Film ... on the current state of the Global medical X-ray ... The report provides a basic overview of the ...
(Date:7/11/2014)... July 11, 2014 On ... down 0.52%, the Dow Jones Industrial Average finished the day ... 1,964.68, down 0.41%. The losses were broad based as eight ... S&P 500 Health Care Sector Index ended the day at ... the last one month. Investor-Edge has initiated coverage on the ...
(Date:7/11/2014)... SAN DIEGO , July 11, 2014 ... Therapies Corp. ("Biotie") to end the option held by ... to commence further development of NRL-1 (intranasal diazepam) for ... seizures. Over the past year, Biotie has ... Neurelis in preparation for the pivotal clinical work required ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
(Date:7/13/2014)... 13, 2014 Max International ... Mullin, will be the featured guest at its Charity ... Puerto Rico. Attendees will learn about Max’s health ... two exhibition basketball games and perform in a 3 ... of health- and energy-boosting supplements , has recently announced ...
(Date:7/13/2014)... Dallas, Texas (PRWEB) July 13, 2014 ... of aGVHD in the 6MM, from 8,062 diagnosed incident ... 2023, at an Annual Growth Rate (AGR) of 4.35%, ... have the highest number of diagnosed incident cases of ... whereas Spain will have the lowest number of diagnosed ...
(Date:7/13/2014)... According to the Kidney Disease Solution book review ... guide on what to do to eliminate the root ... in its review that readers can easily learn what foods ... kidney health. Vkool also informs in its Kidney Disease Solution ... kidney functions naturally. The book consists of a collection of ...
(Date:7/13/2014)... Celebrity fitness trainer and former World ... partnership with Aqua Health Labs for their flagship product ... . The collaboration was recently announced live on ESPN ... , actor, model, and a two time World Super ... he has prepared stars including Demi Moore, Hilary Swank ...
(Date:7/13/2014)... If Dr. Lawrence Power has his way, the ... http://www.HealthYourself101.com will expand people’s understanding of the causes, ... set out to provide a health education platform on this ... we say it? – entertaining to dig into and learn ... the remote learner – the solitary individual signing on from ...
Breaking Medicine News(10 mins):Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
... was more rapid afterward, study finds , , TUESDAY, Oct. ... education seems to delay the onset of dementia, but ... a new study finds. , The findings confirm ... with more education have some kind of brain "reserve" ...
... dont dispute the important role that diet and activity ... eating habits and a less active lifestyle fully explain ... That question has led some researchers to ask whether ... In the October issue of Mayo Clinic Proceedings, researcher ...
... calls for greater collaboration across Europe on research in ... in improved and cost-effective healthcare, the ESF says, but ... and industry if Europe is to realise the full ... The call comes in a new ESF Science Policy ...
... LA JOLLA, Calif., Oct. 23 Immunosyn,Corporation (OTC Bulletin ... as the company,s Chief Executive Officer, President and,board member. ... role at Immunosyn and help,shape the company,s success. I ... life for millions of people who suffer from painful ...
... of fatigue might find some relief through regular exercise ... a new review. , Fatigue is one of ... those undergoing treatment with radiation and chemotherapy. According to ... cancer treatment experience fatigue that can range from mild ...
... McKusick-Nathans Institute of Genetic Medicine today are releasing newly ... Hopkins data, coordinated with a similar data release from ... hereditary factors and speed the understanding of autism by ... look to date at the genetic variation patterns in ...
Cached Medicine News:Health News:Dementia in More Educated Hits Later But Harder 2Health News:Mayo Clinic Proceedings article explores possible link between obesity and viral infections 2Health News:Mayo Clinic Proceedings article explores possible link between obesity and viral infections 3Health News:Improving Europe's image 2Health News:Immunosyn Corporation Names Stephen Ferrone as CEO 2Health News:Exercise and psychological counseling could ease cancer-related fatigue 2Health News:Exercise and psychological counseling could ease cancer-related fatigue 3Health News:Hopkins researchers release genome data on autism 2
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
... intraocular lenses. The instrument consists of a ... implant and divides the implant into two ... halves of the lens so that unwanted ... chamber is avoided. The instrument is passed ...
Hydroview insertion forcep with very thin jaws to allow insertion through tunnel or clear cornea incision. Locking. Made in titanium....
Angled insertion forcep used for the Hydroview lens. Manufactured in titanium....
Medicine Products: